Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Celldex Therapeutics, Inc. (NASDAQ: CLDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Celldex is a biopharmaceutical company focused on antibody-based therapies in immunology, and its filings offer detailed information on clinical programs, financial position and material events affecting the business.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports for discussions of Celldex’s pipeline, including barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), symptomatic dermographism (SD), prurigo nodularis (PN) and atopic dermatitis (AD), as well as the bispecific antibody CDX-622. These reports typically describe the company’s focus on mast cell biology, key risk factors, research and development spending and overall operating results.
Form 8-K current reports capture material events such as clinical trial readouts and financial updates. Recent examples include 8-K filings referencing topline Phase 2 results for barzolvolimab in eosinophilic esophagitis (EoE) and quarterly financial results press releases. These documents help readers track how new data and business developments are communicated to regulators and the market.
Through Stock Titan, users can also access Section 16 filings such as Form 4, where available, to monitor insider transactions in CLDX common stock, and proxy-related filings that discuss governance and executive matters. AI-powered summaries on this page are designed to explain the key points of lengthy filings, highlight clinically and financially relevant sections, and make it easier to compare updates over time.
All filings are sourced directly from EDGAR and updated as new documents are submitted, giving investors, analysts and researchers a structured view of Celldex’s regulatory history and ongoing disclosure around its immunology-focused programs.